Insight

Vanita Noronha: Neoadjuvant paclitaxel+platinum to 5-fluorouracil+platinum in esophageal/GEJ squamous cell carcinoma

Photo of Vanita Noronha/uhapo

Sep 30, 2024, 17:03

Vanita Noronha: Neoadjuvant paclitaxel+platinum to 5-fluorouracil+platinum in esophageal/GEJ squamous cell carcinoma

Vanita Noronha, Medical Oncologist at Tata Memorial Hospital, shared an article on X:

“For locally advanced Esophageal Cancer, pacli+ platiunum is non-inferior to 5FU-platinum, with less side effects and higher pCR of 26%.”

Tittle: Phase III randomized trial comparing neoadjuvant paclitaxel+platinum to 5-fluorouracil+platinum in esophageal/GEJ squamous cell carcinoma

Authors: Vanita Noronha, Vijay Maruti Patil, Nandini Menon, Amit Joshi, Minit Jalan Shah, Ajaykumar Singh, Supriya Goud, Srushti Shah, Sucheta, Kavita Nawale, Dipti Nakti, Akanksha Yadav, Shweta Jogdhankar, Rajeev Kumar, Virendra Kumar Tiwari, Devayani Niyogi, Nilendu Purandare, Amit Janu, Nivedita Chakrabarty, Abhishek Mahajan, Anil Tibdewal, Jaiprakash Agarwal, Akash Pawar, Oindrila Roy Chowdhury, Vibhor Sharma, Venkatesh Kapu, Mehak Trika, Srigadha Vivek Kumar, Manali Kolkur, Priyanka Bhagyavant, Zoya Peelay, Rutvij Khedkar, Medha Jain, Rajendra Badwe and Kumar Prabhash.

Source: Vanita Noronha/X

5FU-platinum cancer esophageal cancer Kumar Prabhash Manali Kolkur Medha Jain Nandini Menon OncoDaily Oncology Priyanka Bhagyavant Rajendra Badwe Rutvij Khedkar squamous cell carcinoma Srigadha Vivek Kumar Tata Memorial Hospital Vanita Noronha Vijay Maruti Patil Zoya Peelay

Faster, Flexible and Affordable: Mikhail Groubman on Building a Global Legacy in Clinical Research in an Untapped Market

Invest in Health Policy: A Conversation with Professor Andreas Charalambous

FDA Approves Cosibelimab-ipdl for Treatment of Metastatic or Locally Advanced Cutaneous Squamous Cell Carcinoma

Dolph Lundgren’s Fight for Life: How He Survived Kidney Cancer After 9 Years of Battle

Agenus and Tanner Pharma Partner to Expand Global Access to BOT/BAL

Special Coverage